Argenica Therapeutics Ltd (AU:AGN)
ASX:AGN
Total Valuation
Argenica Therapeutics Ltd has a market cap or net worth of AU$18.63M. The enterprise value is AU$14.23M.
Market CapAU$18.63M
Enterprise ValueAU$14.23M
Share Statistics
Argenica Therapeutics Ltd has 128,456,710 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding128,456,710
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Argenica Therapeutics Ltd’s return on equity (ROE) is -0.99 and return on invested capital (ROIC) is -106.15%.
Return on Equity (ROE)-0.99
Return on Assets (ROA)-0.65
Return on Invested Capital (ROIC)-106.15%
Return on Capital Employed (ROCE)-1.06
Revenue Per Employee459.11K
Profits Per Employee-1.02M
Employee Count7
Asset Turnover0.29
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Argenica Therapeutics Ltd is ―. Argenica Therapeutics Ltd’s PEG ratio is -2.24.
PE Ratio―
PS Ratio30.16
PB Ratio13.39
Price to Fair Value13.39
Price to FCF-16.99
Price to Operating Cash Flow-2.93
PEG Ratio-2.24
Income Statement
In the last 12 months, Argenica Therapeutics Ltd had revenue of 3.21M and earned -7.17M in profits. Earnings per share was -0.06.
Revenue3.21M
Gross Profit3.21M
Operating Income-7.68M
Pretax Income-7.17M
Net Income-7.17M
EBITDA0.00
Earnings Per Share (EPS)-0.06
Cash Flow
In the last 12 months, operating cash flow was -5.70M and capital expenditures 0.00, giving a free cash flow of -5.70M billion.
Operating Cash Flow-5.70M
Free Cash Flow-5.70M
Free Cash Flow per Share-0.04
Dividends & Yields
Argenica Therapeutics Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.11
52-Week Price Change-78.03%
50-Day Moving Average0.23
200-Day Moving Average0.37
Relative Strength Index (RSI)25.89
Average Volume (3m)511.75K
Important Dates
Argenica Therapeutics Ltd upcoming earnings date is Mar 2, 2027, Before Open (Confirmed).
Last Earnings DateFeb 10, 2026
Next Earnings DateMar 2, 2027
Ex-Dividend Date―
Financial Position
Argenica Therapeutics Ltd as a current ratio of 2.90, with Debt / Equity ratio of 0.00%
Current Ratio2.90
Quick Ratio2.90
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Argenica Therapeutics Ltd has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Argenica Therapeutics Ltd EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -15.14.
EV to Sales26.87
EV to EBITDA0.00
EV to Free Cash Flow-15.14
EV to Operating Cash Flow-15.14
Balance Sheet
Argenica Therapeutics Ltd has AU$10.56M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of AU$10.56M billion.
Cash & Marketable SecuritiesAU$10.56M
Total DebtAU$0.00
Net CashAU$10.56M
Net Cash Per ShareAU$0.08
Tangible Book Value Per ShareAU$0.06
Margins
Gross margin is 100.00%, with operating margin of -239.05%, and net profit margin of -223.11%.
Gross Margin100.00%
Operating Margin-239.05%
Pretax Margin-223.11%
Net Profit Margin-223.11%
EBITDA Margin0.00%
EBIT Margin-239.05%
Analyst Forecast
The average price target for Argenica Therapeutics Ltd is AU$0.64, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price TargetAU$0.64
Price Target Upside357.14% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast-5.68%